并非所有出血的情况都是英夫利昔单抗难治性溃疡性结肠炎。
All that bleeds is not infliximab-refractory ulcerative colitis.
作者信息
Law J K, Salh B, Yoshida E M
机构信息
Division of Gastroenterology, University of British Columbia, and Gastroenterology Clinic, St Paul's Hospital, Vancouver, British Columbia, Canada.
出版信息
Can J Gastroenterol. 2009 Feb;23(2):91-2. doi: 10.1155/2009/983121.
The role of biological agents in moderate to severe ulcerative colitis has been shown to be effective in the induction of clinical remission. However, the role of infliximab therapy for induction of remission in patients with fulminant colitis is debatable. A case of a hospitalized patient with a new diagnosis of severe ulcerative colitis refractory to intravenous steroids is presented. The patient was treated with infliximab and discharged with clinical remission, but subsequently presented back to hospital with a lower gastrointestinal hemorrhage.
生物制剂在中重度溃疡性结肠炎中的作用已被证明对诱导临床缓解有效。然而，英夫利昔单抗治疗暴发性结肠炎患者诱导缓解的作用存在争议。本文介绍了一例新诊断为重度溃疡性结肠炎且对静脉注射类固醇难治的住院患者。该患者接受英夫利昔单抗治疗后临床缓解出院，但随后因下消化道出血再次入院。
Zotero 插件